RALEIGH – November 02, 2026 -- RedHill Biopharma (NASDAQ: RDHL) said two independent in vitro studies confirmed that its Crohn's disease candidate RHB-204 kills Mycobacterium avium subspecies paratuberculosis (MAP) at a level comparable to RHB-104, which posted a 64% efficacy gain in a Phase 3 trial.

Raleigh, N.C. – September 04, 2026 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) has acquired exclusive global commercialization rights to Ferring Pharmaceuticals' Rebyota and exclusive U.S. rights to Clenpiq, two FDA-approved gastrointestinal drugs that together generated approximately $37.5 million in 2025 net sales.